Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Fibrosis: early-phase trial registry
10 of 23 indexed Pulmonary Fibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 10 currently recruiting · #724 of 28,707 conditions by registered trial count
Pulmonary Fibrosis: 23 US clinical trials tracked, 10 recruiting.
Pulmonary Fibrosis is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 3 of these trials.
Enrollment posture brief
Registry condition pulmonary-fibrosis
OPEN 10 | RECR 43% | LATE 1 | EARLY 6 | RANK #724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Pulmonary Fibrosis lists 10 open slots (43% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Fibrosis is recruiting above its size-band peers.
10 of 23 indexed trials (43.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pulmonary Fibrosis trials is spread across many organizations.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 3 of 23 trials (13%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Pulmonary Fibrosis enrolment sits around 100 participants.
Median target enrolment is 100 among the 23 trials that report a genuine target (sentinel values excluded). 11 of those (47.8%) plan for fewer than 100 participants.
-
Pulmonary Fibrosis splits between interventional and observational designs.
11 interventional and 12 observational studies make up this index (47.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
Pulmonary Fibrosis Foundation Community Registry
Pulmonary Fibrosis Foundation
NCT05382572
Role of Genetic Factors in the Development of Lung Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001532
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
University of Pittsburgh
NCT00258570
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center
NCT05392881
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
University of California, Los Angeles
NCT06162884
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Massachusetts General Hospital
NCT03535545
Explanted Lung Tissues With Pulmonary Fibrosis
University of Chicago
NCT00515567
Advanced Imaging for Pulmonary Fibrosis
Peter Caravan
NCT06532071
FAPI PET for Lung Fibrosis
University of California, Los Angeles
NCT05365802
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health Professions
NCT06304207
Advancing Prevention of Pulmonary Fibrosis
University of Colorado, Denver
NCT04564183
Post Acute Sequelae of COVID-19
Vanderbilt University Medical Center
NCT04964115
Analysis of Specimens From Individuals With Pulmonary Fibrosis
National Human Genome Research Institute (NHGRI)
NCT00084305
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
University of Pittsburgh
NCT00258544
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
University of Chicago
NCT04948203
Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001885
Segmental Bronchoalveolar Lavage
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001618
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Icahn School of Medicine at Mount Sinai
NCT04619680
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
Boehringer Ingelheim
NCT05670587
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
University of North Carolina, Chapel Hill
NCT01615484
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Thomas Hope
NCT05180162
A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
NYU Langone Health
NCT00563212
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
Johns Hopkins University
NCT04170062
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Fibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Fibrosis page
23 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Pulmonary Fibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Pulmonary Fibrosis trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Fibrosis condition card totals 23 registered trials; most-linked intervention [68Ga]CBP8; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.